Clinical Study


Posted Date: Jul 16, 2020

  • Investigator: Jean Elwing
  • Specialties:
  • Type of Study: Observational/Survey

A prospective, multicenter study to identify biomarker signatures in patients with pulmonary hypertension (PH).


All Participants Must Be 18 Years Of Age Or Older, Sign The Informed Consent Form And Be Medically Stable At Screening. The Study Population Will Consist Of Prevalent And Incident Patients. With This, He Or She Must Have Undergone A Rhc Within 18 Months (Prevalent Ph Patients), 6 Months (Prevalent Non-Ph Patients) Or 6 Weeks (Incident Patients) To Be Eligible For Enrollment. Patients On Dialysis, Have A History Of Lung Or Heart Transplant, Severe Left Ventricular Dysfunction Or Ejection Fraction Of <35%, An Ongoing Contagious Respiratory Disease, Have Contributed Blood Samples For The Actelion Retrospective Study Of Biomarkers For Ph, Or Are Unable To Have At Least Two 10Ml Tubes Of Blood Drawn Are Not Eligible To Participate In The Study. Additionally, Incident Patients Are Ineligible If They Have Received Pharmacological Treatment For Ph Prior To Collection Of Biomarker Samples.


Pulmonary Hypertension, Biomarkers

For More Information:

Jessica Anderson
(513) 558-3077

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.